05/17/2026
NICELY SUMMARIZED
A woman is told her bladder cancer has come back. Then she is told something stranger: there is a therapy the FDA approved for exactly this - and she still might not be able to get it.
Not because it failed her. Not because she can't afford it. Because it only works paired with a second drug, and that second drug has been in short supply in this country for more than a decade.
THE PROBLEM
First, what BCG is. It is the standard treatment for early bladder cancer, and has been for roughly fifty years. It is not a chemical drug. It is a live, weakened bacterium - the same one first used as the tuberculosis vaccine - put directly into the bladder to wake the immune system up against the cancer. Bladder cancer was treated with immunotherapy decades before the word was fashionable. It works. The hard part has always been getting it.
ANKTIVA is FDA-approved for bladder cancer that comes back despite BCG. The label does not say "ANKTIVA." It says ANKTIVA in combination with BCG.
So the rescue therapy for a patient whose cancer survived BCG needs more BCG.
And BCG in the United States has had one FDA-approved supplier - Merck - and one strain, in shortage since 2012, more than a decade, and allocated by Merck for years. Doctors splitting doses. Delaying patients. Turning people away.
An approved drug whose approved regimen could not always be filled. That is the problem nobody was solving.
WHAT HAPPENED SATURDAY
On Saturday, May 16, on stage at the American Urological Association annual meeting, ImmunityBio announced it had secured exclusive U.S. rights to a second source of BCG - the Tokyo-172 strain. ImmunityBio, not the manufacturer in Japan, would be the one to take it to the FDA.
Not a promise. A signed agreement, with the head-to-head trial already done.
THE DATA
The proof is SWOG S1602: a randomized Phase 3 trial run by the National Cancer Institute through a federally funded cooperative group, in patients getting BCG for the first time - the standard first-line setting. It put the Tokyo-172 strain head to head against the only BCG the FDA has approved. Presented by Svatek and colleagues at the ASCO genitourinary symposium, 2026.
The results:
- High-grade recurrence-free survival: Tokyo-172 non-inferior to the standard strain. Pre-specified non-inferiority bar met.
- 5-year high-grade recurrence-free survival: 64 percent (Tokyo-172) vs 58 percent (standard).
- This held for the straight intravesical schedule. A separate priming schedule in the same trial did not.
- Serious (grade 3-4) side effects: higher with Tokyo-172 than the standard strain.
In plain English:
"Non-inferior" means the new BCG was statistically shown to be not worse than the old one at keeping high-grade cancer from coming back. The trial set a bar in advance for how much worse it could be and still count as equivalent; Tokyo-172 stayed inside that bar. This is the result that matters for a shortage: a second source proven non-inferior in a government-run trial - not a marginally better drug.
Five years out, 64 of every 100 patients on Tokyo-172 had no high-grade recurrence, versus 58 of every 100 on the standard strain. Directionally favorable, but the trial's claim - and the honest claim - is equivalence, not superiority.
Two caveats that belong in the open: only the standard intravesical way of giving it worked; a different dosing schedule tested in the same trial failed. And serious side effects were more common with Tokyo-172. This is "as effective, by the government's own randomized data" - not "gentler."
THE PATH
Who does what, and exactly where this stands.
Done:
- The trial. SWOG S1602 was designed, run and analyzed by the National Cancer Institute and the SWOG cooperative group - publicly funded, independent of the company. It showed Tokyo-172 non-inferior to the approved strain.
- The supply. Japan BCG Laboratory, which has made this strain for decades, signed an exclusive U.S. development and supply agreement with ImmunityBio on May 16, 2026.
- The rights. ImmunityBio - not the Japanese manufacturer - is the sole U.S. applicant. ImmunityBio is the one that will file with the FDA and would hold the U.S. license.
Not yet:
- The data agreement. To use the SWOG S1602 results in a filing, ImmunityBio is still negotiating a Data Use Agreement with SWOG, the NCI and Fred Hutchinson. In discussion. Not signed.
- The FDA conversation. Engagement with the FDA on the approval path is, in the company's own words, still "to be initiated."
- The filing. The Biologics License Application is planned. It has not been filed.
- The decision. No FDA review. No approval. No date - the company has given no timeline.
- The patient. Until all of that, a U.S. patient still cannot get Tokyo-172.
What changed on Saturday is not availability. It is that the road now exists - and it runs on data the government already paid for.
WHO WAS WAITING ON WHOM
The data that underwrites this was generated by the National Cancer Institute. Federal money. A public trial. Sitting in the public domain.
Two days after the Saturday announcement - Monday, May 18 - the FDA's own Oncology Center of Excellence holds a public workshop on contemporary issues in non-muscle invasive bladder cancer. The BCG shortage and what it does to clinical trials is on the agenda. The exact problem.
The company is not on that agenda. It does not speak there. It does not need to. It had addressed the regulator's own stated problem two days before the regulator's independent panel sat down to discuss it - using a randomized trial the government itself paid for and ran. Days earlier, in public, the founder had already named the frame: "S1602 is the kind of rigorous, publicly funded science that should inform FDA decision-making."
ANNOUNCED, NOT HEARD
There was a press release. There was a post from . None of it was hidden. It still didn't land - because supply agreements are not supposed to be dramatic, a licensing deal does not trend, and it crossed the wire on a Saturday as a few words about "exclusive U.S. supply." Most people filed it under logistics and scrolled on.
Here is what they scrolled past: a company whose only approved drug legally requires a partner product it never controlled - BCG, rationed by Merck, which competes in the same disease with its own drug - just took exclusive U.S. rights to a second, trial-proven source of it.
WHAT THIS WAS REALLY FOR
The supply story is not even the real story. The woman in this post is in the smaller group: patients whose cancer already came back after BCG. But BCG is given far earlier - it is the standard first treatment for the disease. That first-line group is several times larger than the one the approved drug covers today.
That is exactly where ImmunityBio's next bladder-cancer application is aimed: its first-line trial, QUILT-2.005, behind a BCG-naive filing the company has guided for the end of 2026 - a far larger patient population than the approved use it sells now.
That filing is also a BCG regimen. The company could not deliver it at scale without a BCG supply it controls.
So the order matters. Secure a proven BCG first - validated by the government, in exactly that first-line population - then file. The supply deal was not the headline. It was the precondition for the one still to come.
THE MISSING HALF
For two years, the question about this therapy was never whether it works. It was whether the patient could ever get all of it.
That question used to have no good answer. A single supplier. A decade of shortage. Nothing a company could do about the half it didn't own.
It owns it now. The proof is done and public. The approval is not.
For the first time, what stands between the patient and a complete, approved therapy is a regulatory path - not a shortage.
